ERBB2 and gastric cancer: In 2010, the international phase III randomized trastuzumab for gastric cancer (ToGA) trial, for the first time showed a significant overall survival (OS) improvement from the administration of trastuzumab, an anti-HER2 monoclonal antibody, in combination with platinum-based chemotherapy compared to chemotherapy alone in patients with HER2-positive advanced GEA (combining GC and GEJ tumors) [21].